- OncoCyte (NYSEMKT:OCX) -46% following unsuccessful results from a clinical validation study of DetermaDx.
- Zynerba Pharmaceuticals (NASDAQ:ZYNE) -40% after Zygel flunks Fragile X study.
- Liquidia Technologies (NASDAQ:LQDA) -20% after pricing equity offering.
- Genworth Financial (NYSE:GNW) -17% after extending merger agreement with Oceanwide.
- Puhui Wealth Investment Management (NASDAQ:PHCF) -16%.
- Inovio Pharmaceuticals (NASDAQ:INO) -10%.
- PDS Biotechnology (NASDAQ:PDSB) -10%.
- Fuel Tech (NASDAQ:FTEK) -9%.
- Electrameccanica Vehicles (NASDAQ:SOLO) -9%.
- Trinity Biotech (NASDAQ:TRIB) -7%.
- IBio (NYSEMKT:IBIO) -7%.
- Kitov Pharma (NASDAQ:KTOV) -7%.
- Vaxart (NASDAQ:VXRT) -7%.
- Boxlight (NASDAQ:BOXL) -6%.
- Ekso Bionics Holdings (NASDAQ:EKSO) -6%.
- CleanSpark (NASDAQ:CLSK) -6%.
- Innovative Industrial Properties (NYSE:IIPR) -5% after pricing stock offering.
- BOQI International Medical (NASDAQ:BIMI) -5% on Q1 results.